2018 OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

MEASURE TYPE:
Process

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

INSTRUCTIONS:
This measure is to be submitted a minimum of once per performance period for all myelodysplastic syndrome (MDS) patients seen during the performance period, regardless of when erythropoietin therapy is initiated; the quality action being measured is that iron stores were documented for each MDS patient receiving erythropoietin therapy within 60 days of starting erythropoietin therapy, regardless of how far back the erythropoietin therapy initiated. It is anticipated that eligible clinicians who provide services for patients with the diagnosis of myelodysplastic syndromes will submit this measure.

Measure Submission:
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy

DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for registry-based measures

Definition:
Erythropoietin Therapy – Includes the following medications: epoetin and darbepoetin for the purpose of this measure.

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter
AND
Diagnosis for MDS (ICD-10-CM): D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.A, D46.B, D46.C, D46.Z
AND
Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*
WITHOUT
Telehealth Modifier: GQ, GT, 95, POS 02
AND
Patient receiving erythropoietin therapy: 4090F

**NUMERATOR:**
Patients with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

**NUMERATOR NOTE:** Denominator Exception(s) are determined during the 60 days prior to initiating erythropoietin therapy.

**Definition:**
Documentation of Iron Stores – Includes either: 1) bone marrow examination including iron stain OR 2) serum iron measurement including ferritin, serum iron and total iron-binding capacity (TIBC).

**Numerator Options:**
- **Performance Met:** Documentation of iron stores prior to initiating erythropoietin therapy (3160F)
- **Denominator Exception:** Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy (3160F with 3P)
- **Performance Not Met:** Iron stores prior to initiating erythropoietin therapy not documented, reason not otherwise specified (3160F with 8P)

**RATIONALE:**
In comparison with supportive care alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus supportive care had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation Treatment of anemia in MDS with EPO plus G-CSF was associated with significantly improved survival outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation. Erythropoiesis-stimulating agents (ESAs: erythropoietin-alfa, darbepoetin) are a key component of the strategy for improving anemia and reducing dependence on red blood cell (RBC) transfusions. Clinical trial results indicate that approximately 40% of selected patients have a clinically meaningful hemoglobin response to ESAs, with a median two-year response. To be effective, erythropoietin therapy requires that adequate iron stores be present due to iron’s importance in red-blood-cell synthesis. By promoting the documentation of adequate iron stores in MDS patients requiring EPO therapy, the efficacy of the treatment will be enhanced.

**CLINICAL RECOMMENDATION STATEMENTS:**
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines:

Anemia related to MDS commonly presents as a hypoproducive macrocytic anemia, often associated with suboptimal elevation of sEpo levels. Bone marrow aspiration with iron stain, biopsy, and cytogenetics should be used to determine WHO subtype, iron status, and the level of ring sideroblasts. Patients should be considered for HLA-DR15 typing. Iron repletion needs to be verified before instituting Epo or darbepoetin therapy. (Category 2A Recommendation) (NCCN, 2017)

Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin saturation, or ferritin levels and instituting iron repletion when indicated may help to reduce the need for ESAs, maximize symptomatic improvement for patients, and determine the reason for failure to respond adequately to ESA therapy. (ASH, 2010)

**COPYRIGHT:**
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the PCPI® Foundation (PCPI®) or American Society of Hematology (ASH). Neither ASH, nor the American Medical Association (AMA), nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), nor PCPI, nor their members shall be responsible for any use of the Measures.

The AMA’s and AMA-PCPI’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. ASH is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of August 15, 2014.

ASH encourages use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2017 PCPI® Foundation and American Society of Hematology. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2018 Registry Flow for Quality ID #68 NQF # 0378:
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

**SAMPLE CALCULATIONS:**

Data Completeness =
- Performance Met (a=49 patients) - Denominator Exception (b=10 patients) - Performance Not Met (c=20 patients) = 79 patients = 87.69%
- Eligible Population / Denominator (d=89 patients) = 88 patients

Performance Rate =
- Performance Met (a=49 patients) / Eligible Population (79 patients) = 49 patients = 61.63%

*See the posted Measure Specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process
2018 Registry Flow for Quality ID
#68 NQF #0378: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry data submission.

1. Start with Denominator

2. Check Patient Age:
   a. If the Patient Age is greater than or equal to 18 Years of age at Date of Service equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If the Patient Age is greater than or equal to 18 Years of age at Date of Service equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis for MDS as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis for MDS as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.

5. Check Telehealth Modifier:
   a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing.
   b. If Telehealth Modifier equals No, proceed to check Receiving Erythropoietin Therapy.

6. Check Receiving Erythropoietin Therapy:
   a. If Receiving Erythropoietin Therapy equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Receiving Erythropoietin Therapy equals Yes, include in the Eligible Population.

7. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.

8. Start Numerator

9. Check Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy:
a. If Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals Yes, include in Data Completeness Met and Performance Met.

b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation.

c. If Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals No, proceed to Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy.

10. Check Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy:

a. If Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals Yes, include in Data Completeness Met and Denominator Exception.

b. Data Completeness Met and Denominator Exception is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation.

c. If Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals No, proceed to Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified.

11. Check Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified:

a. If Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified equals Yes, include in the Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation.

c. If Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified equals No, proceed to Data Completeness Not Met.

12. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS:

<table>
<thead>
<tr>
<th>Data Completeness</th>
<th>Performance Met (a=40 patients) + Denominator Exception (b=10 patients) + Performance Not Met (c=20 patients) =</th>
<th>70 patients = 87.50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Rate</td>
<td>Performance Met (a=40 patients) =</td>
<td>40 patients = 66.67%</td>
</tr>
<tr>
<td></td>
<td>Data Completeness Numerator (70 patients) – Denominator Exception (b=10 patients) =</td>
<td>60 patients</td>
</tr>
</tbody>
</table>